Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Understanding of antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) principles has advanced, enabling targeted drug design.
• Optimizing oral agents for resistant pathogens is challenging for many current antibiotics.
• Aminopenicillins like amoxicillin offer linear PK and a favorable safety profile.

Purpose of the Study:

• To design and evaluate a novel oral formulation of amoxicillin/clavulanate using PK/PD principles.
• To achieve eradication of Streptococcus pneumoniae with amoxicillin minimum inhibitory concentrations (MICs) up to 4 mg/L.
• To improve treatment of respiratory tract infections caused by resistant bacteria.

Main Methods:

• Development of a unique bilayer tablet combining sustained-release and immediate-release amoxicillin with clavulanate potassium.
• Administration of two tablets twice daily (totaling 2000/125 mg).
• PK/PD modeling to predict efficacy based on time above MIC (T > MIC).

Main Results:

• The new formulation achieved a T > MIC of 49% at amoxicillin MICs of 4 mg/L and 60% at MICs of 2 mg/L.
• This exceeds the PK/PD target of 35-40% T > MIC for bacteriological efficacy.
• The formulation is designed to eradicate penicillin-resistant S. pneumoniae and beta-lactamase-producing pathogens.

Conclusions:

• The enhanced oral amoxicillin/clavulanate formulation demonstrates improved PK/PD properties.
• This formulation is predicted to be highly effective against drug-resistant S. pneumoniae and other common respiratory pathogens.
• PK/PD-guided drug design offers a promising strategy for combating antimicrobial resistance.